Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3415727 | 0.81 | TAS1R3 (0.33) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3414974 | 0.80 | — | — | |
| SCHEMBL3418290 | 0.78 | CALM1 (0.32) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL8822690 | 0.76 | TP53 (0.40) | TP53CYP2D6CYP2C9ALOX15CYP2C19 | |
| SCHEMBL3419449 | 0.76 | TP53 (0.57) | TP53CYP2D6CYP2C9ALOX15CYP2C19 | |
| SCHEMBL27474843 | 0.75 | CNR1 (0.35) | PTGDR2CTSSCTSK | |
| SCHEMBL3420429 | 0.74 | L3MBTL1 (0.36) | PTGDR2 | |
| SCHEMBL3418031 | 0.72 | CA2 (0.40) | TP53ALOX15PTGDR2 | |
| SCHEMBL8088903 | 0.72 | ALOX15 (0.55) | TP53CYP2D6CYP2C9ALOX15CYP2C19 | |
| SCHEMBL3421152 | 0.72 | CYP19A1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2597114-B1 | Organic-inorganic composite materials containing triazine rings and electrical devices using the same | HITACHI LTD (JP) | 2017-03-15 | — | — | EP | disclosed |
| US-9090796-B2 | Organic-inorganic composite materials containing triazine rings and electrical devices using the same | HITACHI, LTD. (JP) | 2015-07-28 | — | — | US | disclosed |
| EP-2597114-A1 | Organic-inorganic composite materials containing triazine rings and electrical devices using the same | Hitachi Ltd. (JP) | 2013-05-29 | — | — | EP | disclosed |
| US-20130131248-A1 | ORGANIC-INORGANIC COMPOSITE MATERIALS CONTAINING TRIAZINE RINGS AND ELECTRICAL DEVICES USING THE SAME | HITACHI, LTD. (JP) | 2013-05-23 | — | — | US | disclosed |
| US-7767739-B2 | Cyanato group-containing cyclic phosphazene compound and method for producing the same | FUSHIMI PHARMACEUTICAL CO., LTD. (JP) | 2010-08-03 | — | — | US | disclosed |
| US-20090170983-A1 | Cyanato Group-Containing Cyclic Phosphazene Compound and Method for Producing The Same | FUSHIMI PHARMACEUTICAL CO., LTD. (JP) | 2009-07-02 | — | — | US | disclosed |
| US-6225492-B1 | CONTACTING CYANATE CRUDE PRODUCT SOLUTION COMPRISING CYANATE, UNSUBSTITUTED PHENOL AND NON-ALCOHOLIC SOLVENT WITH POOR SOLVENT CONTAINING ALCOHOL AND WATER TO CRYSTALLIZE OR PRECIPITATE SAID CYANATE | SUMITOMO CHEMICAL CO., LTD. (JP) | 2001-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170983-A1 | Cyanato Group-Containing Cyclic Phosphazene Compound and Method for Producing The Same | CENPE, CPNE4, MCM3 | TP53 2390/4885CYP2D6 4754/4885CYP2C9 3033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.